Longitudinal analysis of the in vitro activity of ceftazidime/avibactam versus Enterobacteriaceae, 2012–2016

ConclusionsClinical Enterobacteriaceae isolates, including ESBL-positive phenotypes, collected globally (excluding North America) from 2012–2016 were highly susceptible to ceftazidime/avibactam, suggesting it is a useful agent for serious infections caused by multidrug-resistant organisms belonging to the family Enterobacteriaceae when therapeutic options are limited.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research